Gain Therapeutics, Inc.

NASDAQ:GANX

Biotechnology

Healthcare
$1.18 +3.09%

+$0.06 today

Market cap
$50.33M
Beta
0.16
P/E (TTM)
-3.6
EPS (TTM)
-$0.50
52W Low $1.41High $4.34

Volume 4.26M

Average 0.64M

GANX Effect of Forex Changes

Change in reported cash caused by exchange-rate movements on foreign-currency balances.

Gain Therapeutics, Inc.NASDAQ: GANX

Effect of Forex Changes · Q1 FY2026 · quarter ended Mar 2026

Effect of forex changes dips below year-ago levels

Q1 FY2026 effect of forex changes of $24.8K fell 77.4% year over year, behind the +1464.6% change in trailing-twelve-month effect of forex changes. Sequentially, it fell 74.6% from the prior quarter.

Context

  • Effect of forex changes increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -77.4% toward the trailing-twelve-month pace of +1464.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$24.8K-74.6% QoQ
Last fiscal yearDec 2025
$469.43K+189.0% YoY
LTMMar 2026
$389.12K+1464.6% YoY
Effect of Forex Changes past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-77.4%——
1 year+189.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Effect of Forex Changes history

USD · from the cash flow

Latest · FY2025
469.43K USD
Year-over-year change
+189.0%
4-year CAGR
+46.9%

Effect of Forex Changes vs competitors

How GANX compares with its peers on the latest reported figures

  • GANX's LTM Mar 2026 effect of forex changes of $389.12K is the 2nd largest of the 9 companies compared; the peer median is $0.
  • Its year-over-year change of +1464.6% is the highest of 3, against a peer median of +26.2%.
GANX Competitors Peer median
Effect of Forex Changes for GANX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XBITXBiotech Inc.LTM Mar 2026$1.92M +152.3%——
GANXGain Therapeutics, Inc.LTM Mar 2026$389.12K +1464.6%——
ADAGAdagene Inc.LTM Jun 2024$153.11K —-57.5%18.8%
ACETAdicet Bio, Inc.LTM Mar 2026$3K ———
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$0 -100.0%—0.0%
NTRBNutriband Inc.LTM Apr 2026$0 ——0.0%
FBIOFortress Biotech, Inc.LTM Mar 2026$0 ——0.0%
OSTXOS Therapies IncorporatedLTM Mar 2026$0 ———
TCRXTScan Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding GANX) $0+26.2%-57.5%0.0%

Competitors are the stored peer set for GANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(13.89M)(17.59M)(22.27M)(20.41M)(20.16M)
Depreciation & Amortization15.48K64.17K83.58K84.07K94.05K
Deferred Income Tax00000
Stock-Based Compensation839.37K1.53M3.26M2.39M1.8M
Change in Working Capital(329.78K)1.51M442.23K(1.08M)(1.01M)
Accounts Receivables(63.35K)3.63K000
Inventory00000
Accounts Payables(521.39K)1.07M(643.16K)274.89K(468.61K)
Other Working Capital254.96K444.52K1.09M(1.36M)(537.91K)
Other Non-Cash Items999.87K(206.86K)(383.19K)143.52K804.94K
Operating Cash Flow(12.37M)(14.69M)(18.87M)(18.87M)(18.47M)
Capital Expenditures(94.21K)(118.95K)(15.36K)(22.49K)0
Acquisitions (Net)00000
Purchases of Investments0(17.74M)(1.96M)00
Sales of Investments03.08M12.19M5M0
Other Investing Activities00000
Investing Cash Flow(94.21K)(14.77M)10.22M4.98M0
Debt Repayment(21.95K)(78.77K)(89.07K)(90.88K)(96.5K)
Common Stock Issued42.63M012.73M13.21M28.54M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(841.27K)00(109.36K)0
Financing Cash Flow41.77M(78.77K)12.64M13.01M28.45M
Effect of Forex Changes100.78K(23.8K)488.4K(527.17K)469.43K
Net Change in Cash29.41M(29.57M)4.49M(1.41M)10.46M
Free Cash Flow(12.46M)(14.81M)(18.88M)(18.9M)(18.47M)

Gain Therapeutics, Inc.

NASDAQ:GANX

Intrinsic Alpha fair value

Locked

Current Price

$1.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.